Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
Phathom Pharmaceuticals (PHAT) Stock Price & Analysis
92 Followers
PHAT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.84 - $16.07
Previous Close$7.31
Volume396.87K
Average Volume (3M)427.34K
Market Cap
$306.82M
Enterprise Value$248.51M
Total Cash (Recent Filing)$155.38M
Total Debt (Recent Filing)$97.07M
Price to Earnings (P/E)-1.4
Beta1.14
Next Earnings
May 09, 2023EPS Estimate
-$1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.05
Shares Outstanding41,973,271
10 Day Avg. Volume351,850
30 Day Avg. Volume427,344
Standard Deviation0.17
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$23.80Price Target Upside250.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Phathom Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $5.84 and its highest was $16.07 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Currently, no data Available
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is May 09, 2023 which is in 39 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Feb 28, 2023. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.351 by $0.021.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -$1.26.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 41,973,270 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.351. Following the earnings report the stock price went down -11.753%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Among the largest hedge funds holding Phathom Pharmaceuticals’s share is Gilder Gagnon Howe & Co LLC.. It holds Phathom Pharmaceuticals’s shares valued at 6M.
---
Phathom Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.80 (250.00% Upside)
$23.80 (250.00% Upside)
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $26.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
---
Top 5 ETFs holding PHAT
iShares Core S&P Total U.S. Stock Market ETF
$94.56K
Schwab U.S. Broad Market ETF
$76.30K
Up to five ETFs with an Outperform Smart Score that hold PHAT. The ETFs are listed according to market value of PHAT within the ETF
---
---